By Jeremy Koff, senior consulting editor
October 8, 2026 | Formerly known as MicroTransponder, Austin, TX-based Mobia Medical is commercializing Vivistim, an implanted vagus nerve stimulation system indicated for use during rehabilitation therapy to reduce upper-extremity motor deficits and improve motor function in chronic ischemic stroke patients with moderate to severe arm impairment.
The company’s May initial public offering gives Mobia the capital and visibility to expand a therapy category that remains unusual within neuromodulation. Most implantable neuromodulation products are positioned around symptom management: pain, movement disorders, epilepsy, bladder dysfunction, or sleep apnea. Vivistim is different. Its commercial proposition is that electrical stimulation, delivered at the right moment during rehabilitation, can augment activity-dependent plasticity and help patients recover motor function years after stroke.
The company priced its IPO on May 7, 2026, at $15 per share, selling 10 million shares and raising approximately $150 million in gross proceeds. Its shares began trading on the Nasdaq exchange under the symbol MOBI on May 8.
Richard Foust, president and CEO of Mobia Medical, described the motivation behind the IPO: “The biggest challenge was moving from a clinical validation phase to building the infrastructure required to scale our commercial expansion.” He said commercialization required physician education, hospital programs, reimbursement, and patient awareness; going public provided the capital to accelerate those efforts.
From Tinnitus to Stroke Recovery
The path to its commercial indication was not straightforward. In an interview with Neurotech Reports, Mobia COO Prashant Rawat recalled that MicroTransponder began in 2007 when three friends in the Dallas area set out to build a small, wirelessly-powered implantable sensor.
The first therapeutic application the company explored was tinnitus. MicroTransponder studied whether VNS paired with sound therapy could help remodel auditory processing. Rawat said early human feasibility studies showed promising results. At the same time, UT Dallas investigators were studying paired VNS in post-stroke rehabilitation, with animal studies suggesting improved forelimb recovery.
The company then faced a strategic choice: continue with tinnitus or pivot to stroke rehabilitation, where the clinical need and commercial rationale appeared more compelling. According to Rawat, stroke offered greater strategic and venture interest, an acute-to-chronic care continuum, and a patient population already familiar with invasive interventions.
From a surgical perspective, Rawat described training for Vivistim as relatively straightforward because its cuff electrode is similar to those used in VNS for epilepsy. The existing pool of surgeons trained in VNS implantation reduced the company’s surgical-training burden, often a significant hurdle for a new implantable modality.
“As the platform evolved, we applied the same principle to restorative movement after stroke by re-engaging plasticity in the chronic brain to drive durable functional gains,” said Navzer Engineer, co-founder and CSO at Mobia Medical, explaining the scientific progression from the original tinnitus system to stroke recovery. “The pivot wasn’t a departure from the original vision, but an evolution of technology, by applying it to chronic stroke survivors with limited treatment options and giving them a renewed opportunity for meaningful recovery.”
Rehabilitation and Clinical Evidence
Many stroke survivors plateau after roughly three to six months, although timing varies. As recovery slows, therapy often shifts from trying to restore function toward teaching compensatory strategies. That gap became the opening for Vivistim Paired VNS: not simply to help patients adapt to impairment, but to re-engage restorative rehabilitation after plateau. “So much of the stroke ecosystem has been built around surviving the acute event,” Foust explained. “Once patients enter the chronic phase, many are told to accept the function they’ve lost.” He said Mobia aims to change expectations for stroke recovery.
The Vivistim system includes an implantable pulse generator, an implantable lead attached to the left vagus nerve, stroke application and programming software, and a wireless transmitter for communication and activation during therapy. In clinic-based rehabilitation, the therapist initiates stimulation during task practice to synchronize VNS with specific movements. For prescribed at-home use, the patient can swipe a magnet over the implant site to activate a stimulation session while performing assigned rehabilitation movements.
The mechanism is not that stimulation alone restores movement. Rather, stimulation is paired with attempted movement so that neuromodulatory signaling reinforces the motor activity being practiced. That makes Vivistim as much a rehabilitation-workflow platform as an implant technology, requiring Mobia to build a treatment pathway that connects stroke centers, stroke neurologists, physiatrists, neurosurgeons, occupational therapists, caregivers, and patients.
While the surgical training component has been a relatively easy path, the larger implementation challenge is identifying appropriate chronic stroke patients and coordinating the therapy infrastructure around them. As Rawat stated, “One of the things we had to do was tell therapists that we wanted these patients to get back to improving function. And now, we are going to put in something that helps boost their ability to recover.”
The patient population is large, but not every stroke survivor is an immediate candidate. Patients must be medically appropriate for implantation, cognitively able to participate, motivated to complete therapy, and physically capable of structured rehabilitation. Mobia estimates that applying patient-selection criteria to the U.S. chronic ischemic stroke population reduces the initial addressable group to about 1 million people.
The 108-patient VNS-REHAB pivotal trial found better outcomes with paired VNS plus rehabilitation than with rehabilitation and control stimulation, with the advantage persisting at 90 days. Mobia’s July 2026 announcement summarized a Neurology report on 49 participants followed for two years. Seventy-six percent met the threshold for meaningful improvement on at least one of two motor tests, while mean scores rose 7.5 points on the Fugl-Meyer upper-extremity assessment and 0.63 on the Wolf Motor Function Test. Gains were also seen in daily function and quality of life. Investigators reported no long-term serious adverse events related to the therapy or stimulation through two years of follow-up. Results in 16 participants assessed at three years were favorable, although that sample was small. Mobia is collecting additional post-market data through its GRASP registry, including planned 12-, 24-, and 36-month outcomes.
An August 2026 update to the AHA/ASA guidance on adult stroke rehabilitation added implanted paired VNS as an option for some chronic stroke survivors. The recommendation allows consideration of VNS with intensive, task-oriented therapy for upper-limb impairment. The document also favors continued assessment of function for at least a year. The guidance could make the treatment pathway more familiar to stroke programs, although it is not a product endorsement.
Reimbursement and Commercial Growth
Reimbursement considerations—coding, coverage, and payment levels—will be central as Mobia scales Vivistim. The implant procedure is billed under CPT Code 64568. After receiving transitional pass-through support from 2023 through 2025, the code moved to New Technology APC 1580 on Jan. 1, 2026. CMS’s draft hospital outpatient payment rule for 2027 would retain both that APC and a payment level of approximately $45,000. CMS expects to publish the final rule in November 2026, with changes effective the following January; until then, the 2027 classification and rate may change.
The company’s September corporate investor deck states that Mobia is pursuing a Level 6 APC request, with advocacy in 2026 aimed at a 2027 ruling.
Early revenue growth indicates that Mobia has begun to convert clinical interest into commercial activity. Second-quarter 2026 revenue reached $13.5 million, more than double the $6.7 million reported a year earlier. Gross profit was $11.2 million, producing an 83.2% margin. Operating expenses of $29.2 million contributed to a $21 million net loss as Mobia expanded its commercial organization and increased development and public-company spending. Cash stood at $177.1 million on June 30, with the May IPO contributing about $134 million after offering costs. Management’s full-year revenue forecast is $54 million to $56 million, or 69% to 75% above 2025.
As of the end of 2025, more than 1,000 Vivistim implants had been performed, including approximately 700 during 2025. That base gives Mobia a meaningful starting point, but the company remains early in the process of market development. Success depends on physician and therapist adoption, patient awareness, payer coverage, supplier reliability, and expansion of its sales and clinical support organization.
Mobia’s roadmap includes a next-generation system. Longer-term objectives include label expansion into lower-limb impairment and other stroke etiologies, including intracerebral hemorrhage. These remain company objectives, not additional approved indications.
Competition in Stroke Recovery
Mobia is entering a market with several competing approaches. As reported in the June 2026 issue of Neurotech Business Report, Bioness Medical’s PoNS system, a commercial technology, offers an adjacent approach, using tongue stimulation with therapeutic exercise to address gait deficits rather than upper-limb impairment, while Reach Neuro is developing cervical spinal cord stimulation for arm and hand function. Reach’s early studies emphasized improvements during active stimulation, although some gains were also measured without stimulation.
Kandu’s (formerly Neurolutions) FDA-cleared IpsiHand uses an EEG headset to detect imagined hand movement and trigger a powered handpiece to open and close the affected hand. This noninvasive brain-computer-interface pairs movement intent with mechanical assistance to support neural plasticity and upper-limb recovery after chronic stroke.
Other implantable developers include NeuWire Medical, which is developing a miniature, wirelessly-powered VNS system that automatically pairs stimulation with therapeutic movements, and Enspire DBS Therapy, which is evaluating DBS plus rehabilitation in its RESTORE pivotal trial. CorTec is developing Brain Interchange, an investigational system that records cortical activity and delivers closed-loop stimulation during stroke rehabilitation. Unlike the Vivistim system, these systems remain investigational.
Application Evolution
For Mobia, successful competition will require more than just a new technology or target stimulation point. Durable functional benefit, treatment burden, reimbursement, and the ability to establish coordinated rehabilitation programs will shape adoption.
In the neurotechnology field, Mobia represents a rare commercial effort to use implanted neuromodulation as a driver of functional recovery rather than long-term symptom suppression. Its evolution from wireless sensing to tinnitus to stroke recovery shows how a platform’s commercial application can differ from its founding concept.
For the growing stroke rehab sector, these are exciting times with an increasing number of approaches and companies aimed at helping patients regain function beyond the conventional recovery plateau. As clinical evidence builds and access expands, these technologies could give more stroke survivors the opportunity to make meaningful gains in movement, daily function, and independence—even years after their stroke.
